Announced
Completed
Financials
Tags
Cross Border
Private Equity
Single Bidder
Minority
Biotechnology
genetic medicines
United States
Venture Capital
Completed
Acquisition
Private
Friendly
Synopsis
Novo, Catalio Capital Management and SymBiosis led a $100m Series B extension round in Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems. "At Novo Holdings, our purpose is to improve people’s health and the sustainability of society and the planet. Metagenomi continues to display an impressive track record of rapidly developing novel gene editing systems and advancing them through preclinical validation," Ray Camahort, Novo Partner.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.